Revvity has signed a new license agreement with pharmaceutical major AstraZeneca for the technology underlying the former’s next-generation Pin-point base editing system for modular gene editing.

The Pin-point system and the underlying base editing technology are intended to allow efficient and precise single and multiplex (multi-gene) editing without affecting cell viability or functionality.

The system uses a modified Cas enzyme that only nicks one strand of the Deoxyribonucleic acid (DNA) in comparison to conventional CRISPR technologies which generate double-stranded breaks in the DNA.

According to Revvity, the latest editing system allows for a more controlled approach to the disruption of the gene and base correction.

The Pin-point system is totally modular, which is said to set it apart from other base editing systems and enables the selection of various components to maximise the performance of the gene targets.

The technique has demonstrated base editing in T-cells and iPSCs, proving its potential for use with a variety of cell types and therapeutic applications.

Additionally, Revvity has created a proprietary way to use the base editing mechanism to insert genes to make an allogeneic CAR-T cell treatment by introducing a CAR and deleting immunological markers.

The Pin-point base editing system is a component of Revvity’s cell and gene therapy portfolio, which also includes immunoassays, cell analysis, gene modulation, and editing and optimised AAV.

The portfolio also has lentiviral vector development and manufacturing to improve the specificity, efficacy and safety of cell and gene therapies.

Revvity offers solutions like functional genomics assays, payload design, quality assurance/quality control (QA/QC), and vector optimisation through to characterisation, automation, and process development.

Customers can use the solutions to reach their goals in cell and gene therapy research, development, and manufacturing, said the company.